{"pub": "marketwatch", "url": "https://marketwatch.com/articles/johnson-johnson-opioid-trial-deal-settlement-multidistrict-ohio-51570021778", "downloaded_at": "2019-10-02 15:28:06.568635+00:00", "published_at": "2019-10-02", "title": "Johnson & Johnson Has Struck a Deal to Avoid a Key Opioid Trial", "language": "en", "text": "After losing a high-profile opioid trial over the summer, drugmaker Johnson & Johnson has cut a deal to sit out the next key trial in the sprawling opioid litigation.\n\nThe news comes days after The Wall Street Journal reported that Johnson & Johnson (ticker: JNJ) and a handful of other drugmakers were developing an unusual strategy to settle the opioid claims against them by effectively piggybacking on the deal through which OxyContin maker Purdue Pharmaceutical filed for bankruptcy last month.\n\n...", "description": "After losing a high-profile opioid trial over the summer, drugmaker Johnson & Johnson has cut a deal to sit out the next key trial in the sprawling opioid litigation.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DG117_JNJ100_OR_20191002085151.jpg"}